Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from single-arm phase 2 trials, with complete responses (CRs) in 40%...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Sermer, David, Batlevi, Connie, Palomba, M. Lia, Shah, Gunjan, Lin, Richard J., Perales, Miguel-Angel, Scordo, Michael, Dahi, Parastoo, Pennisi, Martina, Afuye, Aishat, Silverberg, Mari Lynne, Ho, Caleb, Flynn, Jessica, Devlin, Sean, Caron, Philip, Hamilton, Audrey, Hamlin, Paul, Horwitz, Steven, Joffe, Erel, Kumar, Anita, Matasar, Matthew, Noy, Ariela, Owens, Colette, Moskowitz, Alison, Straus, David, von Keudell, Gottfried, Rodriguez-Rivera, Ildefonso, Falchi, Lorenzo, Zelenetz, Andrew, Yahalom, Joachim, Younes, Anas, Sauter, Craig
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556134/
https://ncbi.nlm.nih.gov/pubmed/33002134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados